New therapeutic options for advanced non-resectable malignant melanoma
Standard
New therapeutic options for advanced non-resectable malignant melanoma. / Stadler, Simone; Weina, Kasia; Gebhardt, Christoffer; Utikal, Jochen.
In: ADV MED SCI-POLAND, Vol. 60, No. 1, 03.2015, p. 83-8.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - New therapeutic options for advanced non-resectable malignant melanoma
AU - Stadler, Simone
AU - Weina, Kasia
AU - Gebhardt, Christoffer
AU - Utikal, Jochen
N1 - Copyright © 2015 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
PY - 2015/3
Y1 - 2015/3
N2 - Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.
AB - Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.
KW - Antineoplastic Agents
KW - Disease Progression
KW - Humans
KW - Immunotherapy
KW - Melanoma
KW - Skin Neoplasms
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1016/j.advms.2014.12.002
DO - 10.1016/j.advms.2014.12.002
M3 - SCORING: Review article
C2 - 25596540
VL - 60
SP - 83
EP - 88
JO - ADV MED SCI-POLAND
JF - ADV MED SCI-POLAND
SN - 1896-1126
IS - 1
ER -